DS
SRPT icon

David Shaw’s Sarepta Therapeutics SRPT Stock Holding History

David Shaw’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-474,986
Closed -$8.98M – 5202
2026
Q1 		$10.3M Sell
474,986
-1,065,404
-69% -$20.6M 0.01% 1606
2025
Q4 		$33.1M Sell
1,540,390
-466,635
-23% -$9.83M 0.02% 938
2025
Q3 		$38.7M Sell
2,007,025
-2,471,613
-55% -$44.1M 0.02% 785
2025
Q2 		$76.6M Buy
4,478,638
+4,474,232
+101,549% +$191M 0.05% 407
2025
Q1 		$281K Buy
4,406
+906
+26% +$95.4K ﹤0.01% 3792
2024
Q4 		$426K Sell
3,500
-18,239
-84% -$2.24M ﹤0.01% 3715
2024
Q3 		$2.71M Sell
21,739
-96,101
-82% -$13.3M ﹤0.01% 2457
2024
Q2 		$18.6M Buy
117,840
+30,974
+36% +$3.98M 0.02% 931
2024
Q1 		$11.2M Sell
86,866
-268,667
-76% -$32.9M 0.01% 1285
2023
Q4 		$34.3M Buy
355,533
+263,375
+286% +$25.3M 0.03% 623
2023
Q3 		$11.2M Sell
92,158
-182,761
-66% -$20.7M 0.01% 1221
2023
Q2 		$31.5M Sell
274,919
-576,818
-68% -$74.4M 0.03% 624
2023
Q1 		$117M Buy
851,737
+269,490
+46% +$35M 0.13% 174
2022
Q4 		$75.4M Sell
582,247
-50,614
-8% -$5.87M 0.08% 272
2022
Q3 		$70M Buy
632,861
+371,378
+142% +$37.4M 0.08% 270
2022
Q2 		$19.6M Sell
261,483
-29,925
-10% -$2.2M 0.02% 882
2022
Q1 		$22.8M Sell
291,408
-66,687
-19% -$5.11M 0.02% 943
2021
Q4 		$32.2M Buy
358,095
+270,097
+307% +$23.1M 0.03% 784
2021
Q3 		$8.14M Buy
87,998
+65,680
+294% +$5.06M 0.01% 1672
2021
Q2 		$1.74M Buy
22,318
+8,732
+64% +$662K ﹤0.01% 3087
2021
Q1 		$1.01M Sell
13,586
-9,474
-41% -$874K ﹤0.01% 3097
2020
Q4 		$3.93M Buy
23,060
+13,608
+144% +$2.02M ﹤0.01% 2061
2020
Q3 		$1.33M Sell
9,452
-48,216
-84% -$7.33M ﹤0.01% 2672
2020
Q2 		$9.25M Buy
57,668
+26,608
+86% +$3.62M 0.01% 1232
2020
Q1 		$3.04M Buy
31,060
+27,228
+711% +$3.11M ﹤0.01% 1848
2019
Q4 		$494K Buy
+3,832
New +$387K ﹤0.01% 3404
2019
Q3 		– Sell
-64,395
Closed -$7.61M – 4008
2019
Q2 		$9.79M Buy
+64,395
New +$7.83M 0.01% 1147
2018
Q4 		– Sell
-122,631
Closed -$15.3M – 3975
2018
Q3 		$19.8M Sell
122,631
-291,710
-70% -$39.9M 0.02% 783
2018
Q2 		$54.8M Buy
414,341
+406,264
+5,030% +$38.3M 0.07% 342
2018
Q1 		$598K Sell
8,077
-166,998
-95% -$11.1M ﹤0.01% 2794
2017
Q4 		$9.74M Buy
175,075
+59,384
+51% +$3.15M 0.01% 1043
2017
Q3 		$5.25M Buy
115,691
+65,637
+131% +$2.62M 0.01% 1341
2017
Q2 		$1.69M Buy
50,054
+34,876
+230% +$1.14M ﹤0.01% 2081
2017
Q1 		$449K Sell
15,178
-14,506
-49% -$449K ﹤0.01% 2780
2016
Q4 		$814K Buy
+29,684
New +$1.19M ﹤0.01% 2581
2016
Q2 		– Sell
-751,942
Closed -$13.9M – 3519
2016
Q1 		$14.7M Buy
751,942
+58,202
+8% +$1.02M 0.03% 667
2015
Q4 		$26.8M Sell
693,740
-367,792
-35% -$11.9M 0.04% 506
2015
Q3 		$34.1M Buy
1,061,532
+545,156
+106% +$18.5M 0.05% 421
2015
Q2 		$15.7M Buy
516,376
+259,288
+101% +$5.3M 0.02% 735
2015
Q1 		$3.41M Sell
257,088
-84,206
-25% -$1.12M 0.01% 1645
2014
Q4 		$4.94M Sell
341,294
-420,966
-55% -$7.13M 0.01% 1582
2014
Q3 		$16.1M Sell
762,260
-556,552
-42% -$12.6M 0.02% 808
2014
Q2 		$39.3M Buy
1,318,812
+675,169
+105% +$21.3M 0.05% 403
2014
Q1 		$15.5M Buy
643,643
+12,230
+2% +$312K 0.02% 787
2013
Q4 		$12.9M Buy
631,413
+83,958
+15% +$2.49M 0.02% 954
2013
Q3 		$25.9M Buy
547,455
+145,080
+36% +$5.59M 0.04% 473
2013
Q2 		$15.3M Buy
+402,375
New +$14.4M 0.03% 638

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

David Shaw's SRPT Position: Q2 2026 in Review

David Shaw sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 474,986 shares — an estimated $8.98M sold.

David Shaw first reported a position in SRPT in Q2 2013 and held it in 47 quarters. The position peaked at $117M in Q1 2023. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • David Shaw reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • David Shaw sold 474,986 Sarepta Therapeutics shares in Q2 2026, an estimated $8.98M.
  • David Shaw first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 47 quarters.
  • David Shaw's Sarepta Therapeutics position peaked at $117M in Q1 2023.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.